Adynxx (ADYX) Stock Price, News & Analysis

Company Overview

Adynxx, Inc., a clinical stage biopharmaceutical company, focuses on the development and marketing of transcription factor decoy technologies for the treatment of pain and inflammatory diseases. It is involved in the development of AYX platform of transcription factor decoys, including brivoligide, which is in Phase II clinical development for the reduction of postoperative pain; and AYX2, a pre-clinical candidate intended for the treatment of focal chronic pain. The company was founded in 2007 and is headquartered in San Francisco, California.

Key Stats

• Today's Range: N/A
• 50-Day Range: N/A
• 52-Week Range: N/A
• Volume: 83 shs
• Average Volume: 833 shs
• Market Capitalization: N/A
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

ADYX Stock Analysis - Frequently Asked Questions

How do I buy shares of Adynxx?

Shares of ADYX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

What other stocks do shareholders of Adynxx own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Adynxx investors own include HIVE Digital Technologies (HIVE), Tesla (TSLA), Himax Technologies (HIMX), Nextech3D.AI (NEXCF), REE Automotive (REE), Riot Platforms (RIOT) and Arrival (ARVL).

Company Calendar

• Today: 12/21/2024
• Fiscal Year End: 12/31/2024

Industry, Sector and Symbol

• Stock Exchange: OTCMKTS
• Sector: Medical
• Industry: Surgical & medical instruments
• Sub-Industry: N/A
• Current Symbol: OTCMKTS:ADYX
• CUSIP: N/A
• CIK: 1054274
• Web: www.adynxx.com
• Phone: (415) 512-7740
• Fax: 215-702-8535
• Employees: 6
• Year Founded: N/A

Profitability

• EPS (Most Recent Fiscal Year): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: N/A
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: N/A
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: 830,000
• Free Float: N/A
• Market Cap: N/A
• Optionable: Not Optionable
• Beta: 2.67